JPWO2021163627A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021163627A5 JPWO2021163627A5 JP2022549144A JP2022549144A JPWO2021163627A5 JP WO2021163627 A5 JPWO2021163627 A5 JP WO2021163627A5 JP 2022549144 A JP2022549144 A JP 2022549144A JP 2022549144 A JP2022549144 A JP 2022549144A JP WO2021163627 A5 JPWO2021163627 A5 JP WO2021163627A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- heteroaryl
- aryl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 84
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 83
- 125000003118 aryl group Chemical group 0.000 claims description 79
- 125000001072 heteroaryl group Chemical group 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 71
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 71
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 61
- 229910052736 halogen Chemical group 0.000 claims description 59
- 150000002367 halogens Chemical group 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 23
- 150000002431 hydrogen Chemical group 0.000 claims description 23
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000004900 autophagic degradation Effects 0.000 claims description 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012661 PARP inhibitor Substances 0.000 claims description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 125000004965 chloroalkyl group Chemical group 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 102100020689 Autophagy-related protein 13 Human genes 0.000 description 1
- 101000785138 Homo sapiens Autophagy-related protein 13 Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977039P | 2020-02-14 | 2020-02-14 | |
| US62/977,039 | 2020-02-14 | ||
| PCT/US2021/018038 WO2021163627A1 (en) | 2020-02-14 | 2021-02-12 | Macrocyclic ulk1/2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513793A JP2023513793A (ja) | 2023-04-03 |
| JPWO2021163627A5 true JPWO2021163627A5 (https=) | 2024-02-20 |
| JP2023513793A5 JP2023513793A5 (https=) | 2024-02-20 |
Family
ID=77292762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549144A Pending JP2023513793A (ja) | 2020-02-14 | 2021-02-12 | 大環状ｕｌｋ１／２阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12594277B2 (https=) |
| EP (1) | EP4103183A4 (https=) |
| JP (1) | JP2023513793A (https=) |
| KR (1) | KR20220153582A (https=) |
| CN (1) | CN115515588A (https=) |
| AU (1) | AU2021221162A1 (https=) |
| CA (1) | CA3171185A1 (https=) |
| WO (1) | WO2021163627A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021216440A1 (en) * | 2020-04-20 | 2021-10-28 | Tenova Pharmaceuticals Inc. | Novel protein kinase inhibitors |
| WO2022072668A1 (en) * | 2020-09-30 | 2022-04-07 | Salk Institute For Biological Studies | Patient selection biomarkers for treatment with ulk inhibitors |
| TW202404979A (zh) * | 2022-07-18 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抑制並誘導ｅｇｆｒ降解的大環類化合物、其製備方法及其在醫藥上的應用 |
| WO2024017258A1 (zh) * | 2022-07-19 | 2024-01-25 | 百极弘烨(南通)医药科技有限公司 | Egfr小分子抑制剂、含其的药物组合物及其用途 |
| WO2024233766A1 (en) * | 2023-05-10 | 2024-11-14 | Erasca, Inc. | Macrocyclic ulk1/2 inhibitors and their use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005049021A1 (en) | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
| MXPA06013165A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| WO2006037117A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| MY169441A (en) * | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006129100A1 (en) | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
| WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
| EP2089369B1 (en) | 2006-10-19 | 2011-02-02 | Rigel Pharmaceuticals, Inc. | 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
| DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
| BRPI0810641A2 (pt) | 2007-04-12 | 2019-09-24 | Hoffmann La Roche | "compostos farmacêuticos". |
| WO2008140421A2 (en) * | 2007-05-15 | 2008-11-20 | S*Bio Pte Ltd | Heterocycloalkyl substituted pyrimidine derivatives |
| JP2011505407A (ja) | 2007-12-03 | 2011-02-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン |
| WO2009083185A2 (en) | 2007-12-28 | 2009-07-09 | Fovea Pharmaceuticals Sa | Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders |
| EA024109B1 (ru) | 2008-04-16 | 2016-08-31 | Портола Фармасьютиклз, Инк. | Ингибиторы протеинкиназ |
| WO2009132202A2 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| EA201100078A1 (ru) | 2008-06-25 | 2011-08-30 | Айрм Ллк | Производные пиримидина в качестве ингибиторов киназы |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PL2310492T3 (pl) * | 2008-06-30 | 2015-12-31 | Janssen Biotech Inc | Różnocowanie pluripotencjalnych komórek macierzystych |
| US20120114637A1 (en) | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| US20120165332A1 (en) | 2009-06-18 | 2012-06-28 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
| US20130040310A1 (en) | 2009-12-15 | 2013-02-14 | Salk Institute For Biological Studies | Ulk1 compositions, inhibitors, screening and methods of use |
| WO2011084108A1 (en) | 2010-01-08 | 2011-07-14 | Agency For Science, Technology And Research | Methods and compositions for treating cancer |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| SG10201505217WA (en) | 2010-07-09 | 2015-08-28 | Biogen Hemophilia Inc | Chimeric clotting factors |
| WO2012040602A2 (en) | 2010-09-23 | 2012-03-29 | President And Fellows Of Harvard College | Targeting mtor substrates in treating proliferative diseases |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
| US20120244209A1 (en) | 2011-03-02 | 2012-09-27 | Roth Jack A | Tusc2 therapies |
| JP2014511391A (ja) | 2011-03-07 | 2014-05-15 | フォンダッツィオーネ・テレソン | Ｔｆｅｂリン酸化阻害剤およびその使用 |
| EP2780017A1 (en) | 2011-11-15 | 2014-09-24 | Novartis AG | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
| ES2552518T3 (es) | 2012-02-21 | 2015-11-30 | Merck Patent Gmbh | Derivados cíclicos de diaminopiridina como inhibidores de Syk |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| US20150250808A1 (en) | 2012-10-15 | 2015-09-10 | Vojo P. Deretic | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014098932A1 (en) | 2012-12-17 | 2014-06-26 | The Brigham And Women's Hosptial, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| CN103059030B (zh) | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
| CA2899281C (en) | 2013-01-25 | 2022-05-31 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia |
| WO2014197680A1 (en) | 2013-06-05 | 2014-12-11 | Salk Institute For Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| US10300058B2 (en) | 2014-04-18 | 2019-05-28 | Xuanzhu Pharma Co., Ltd. | Tyrosine kinase inhibitor and uses thereof |
| CA2952787A1 (en) | 2014-06-17 | 2015-12-23 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| DK3185868T3 (da) * | 2014-08-25 | 2022-05-23 | Salk Inst For Biological Studi | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| CN105524045B (zh) | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| WO2016090079A1 (en) | 2014-12-05 | 2016-06-09 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN106188029B (zh) | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
| WO2016196393A2 (en) * | 2015-05-29 | 2016-12-08 | Presage Biosciences, Inc. | Autophagy-inhibiting compounds and uses thereof |
| WO2017024019A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| CN105801603B (zh) | 2016-04-13 | 2018-10-02 | 成都倍特药业有限公司 | 一种具有大环结构的alk抑制剂及其制备方法 |
| EP3528814B1 (en) | 2016-10-18 | 2024-08-14 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders |
| US11180482B2 (en) | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
| JP6684700B2 (ja) | 2016-12-26 | 2020-04-22 | アイシン精機株式会社 | 乗員検知装置 |
| EP3620457A4 (en) | 2017-05-02 | 2021-01-06 | Korea Research Institute of Chemical Technology | PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
| IL325201A (en) | 2019-06-17 | 2026-02-01 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of using them |
| CN115515589A (zh) | 2020-02-14 | 2022-12-23 | 萨克生物研究学院 | Ulk1/2抑制剂及其使用方法 |
| JP2023513797A (ja) | 2020-02-14 | 2023-04-03 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｕｌｋ１／２阻害剤による単剤療法および併用療法 |
| WO2021216440A1 (en) | 2020-04-20 | 2021-10-28 | Tenova Pharmaceuticals Inc. | Novel protein kinase inhibitors |
| WO2022072668A1 (en) | 2020-09-30 | 2022-04-07 | Salk Institute For Biological Studies | Patient selection biomarkers for treatment with ulk inhibitors |
-
2021
- 2021-02-12 KR KR1020227028938A patent/KR20220153582A/ko active Pending
- 2021-02-12 JP JP2022549144A patent/JP2023513793A/ja active Pending
- 2021-02-12 CN CN202180027809.1A patent/CN115515588A/zh active Pending
- 2021-02-12 WO PCT/US2021/018038 patent/WO2021163627A1/en not_active Ceased
- 2021-02-12 AU AU2021221162A patent/AU2021221162A1/en active Pending
- 2021-02-12 US US17/799,634 patent/US12594277B2/en active Active
- 2021-02-12 CA CA3171185A patent/CA3171185A1/en active Pending
- 2021-02-12 EP EP21753844.6A patent/EP4103183A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532652A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| JP2021534108A5 (https=) | ||
| JPWO2021168193A5 (https=) | ||
| JP2020505396A5 (https=) | ||
| JP2007505933A5 (https=) | ||
| JP2017536395A5 (https=) | ||
| JP2021534106A5 (https=) | ||
| JP2016518437A5 (https=) | ||
| RU2000127751A (ru) | Противоопухолевое средство | |
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| JP2016503414A5 (https=) | ||
| JP2022137237A5 (https=) | ||
| JP2018502141A5 (https=) | ||
| JP2002537292A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| RU2005133093A (ru) | Соединения для лечения флавивирусных инфекций | |
| JP2011518168A5 (https=) | ||
| JPWO2021163627A5 (https=) | ||
| JP2005538974A5 (https=) | ||
| JPWO2023083297A5 (https=) | ||
| JPWO2023083285A5 (https=) | ||
| JP2019511485A5 (https=) | ||
| JP2022502378A5 (https=) | ||
| JPWO2021150574A5 (https=) |